TKPHF — TAKEDA PHARMACEUTICAL CO LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1395064 ·
Last close
$32.48
Market Cap
$51.31B
52W High
$37.71
52W Low
$29.33
ADV30
6,927
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,191,698,000,000 | 790,550,000,000 | 168,822,000,000 | 103,640,000,000 | 15,408,774,000,000 | 654,937,000,000 | 7,764,684,000,000 |
| Sep 2025 | 1,112,796,000,000 | 732,735,000,000 | 68,996,000,000 | -11,802,000,000 | 14,470,300,000,000 | 681,486,000,000 | 7,338,611,000,000 |
| Jun 2025 | 1,106,685,000,000 | 722,010,000,000 | 184,565,000,000 | 124,243,000,000 | 14,004,537,000,000 | 350,008,000,000 | 7,138,357,000,000 |
| Mar 2025 | 1,053,399,000,000 | 671,321,000,000 | 68,543,000,000 | -103,155,000,000 | 14,248,344,000,000 | 385,113,000,000 | 7,312,365,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,189,062,000,000
Investing CF
$-330,806,000,000
Financing CF
$-721,117,000,000
CapEx
$-442,990,000,000
Dividends Paid
$-312,852,000,000
Buybacks
$-101,581,000,000
EPS Diluted TTM
$78.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$1,095,662,000,000
Inventory
$1,407,192,000,000
Receivables
$757,921,000,000
ST Investments
$107,004,000,000
EBIT TTM
$496,862,000,000
Pretax Income TTM
$205,369,000,000
Interest Exp TTM
$291,493,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,505,720,061,952
EBITDA
$1,346,403,958,784
Free Cash Flow
$356,631,117,824
Enterprise Value
$4,910,553,235,456
Total Cash
$595,053,969,408
Total Debt
$5,453,085,933,568
Shares Out
1,579,836,830
Trailing EPS
$0.75
Book Value
$30.72
ROE
2.6%
ROA
2.6%
Div Yield
3.99%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 4,581,551,000,000 | 486,061,000,000 | 107,928,000,000 | 14,248,344,000,000 | 7,312,365,000,000 | — | 1,057,182,000,000 |
| Mar 2024 | 4,263,762,000,000 | 366,165,000,000 | 144,067,000,000 | 15,108,792,000,000 | 7,834,787,000,000 | — | 716,344,000,000 |
| Mar 2023 | 4,027,478,000,000 | 587,812,000,000 | 317,017,000,000 | 13,957,750,000,000 | 7,603,079,000,000 | — | 977,156,000,000 |
| Mar 2022 | 3,569,006,000,000 | 546,043,000,000 | 230,059,000,000 | 13,178,018,000,000 | 7,494,495,000,000 | — | 1,123,105,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $48.72B | $15.42 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $62.63B | $607.93 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $37.91B | $32.56 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $37.75B | $282.72 | — |
| TEVJF | TEVA PHARMACEUTICAL INDUSTRIES LTD | $35.33B | $30.34 | — |
News headlines (Yahoo Finance, 1h cache)
Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis
2026-06-16 18:13 · Yahoo
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
2026-06-15 16:00 · Yahoo
AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus
2026-06-15 14:54 · Yahoo
Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test.
2026-06-11 20:15 · Yahoo
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
2026-06-11 11:00 · Yahoo
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
2026-06-11 07:00 · Yahoo
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
2026-06-10 18:08 · Yahoo
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
2026-06-09 20:30 · Yahoo
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton
2026-06-09 12:16 · Yahoo
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
2026-06-05 08:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.